FDA Approves New Use for Abraxane In Combination With Other Cancer Drug

The Food and Drug Administration said Sept. 6 it has expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

The agency said it reviewed the new use for Abraxane under the priority review program, which provides for an expedited review of drugs. Abraxane also was granted orphan product designation for pancreatic cancer because it is intended to treat a rare disease or condition, the FDA added. The drug is made by Celgene Corp., which is based in Summit, N.J.

Celgene said in a release that the approval was ...